Recap: Wynn Resorts Q4 Earnings

Wynn Resorts (NASDAQ:WYNN) reported its Q4 earnings results on Wednesday, February 7, 2024 at 04:02 PM. Here’s what…

Wynn Resorts (NASDAQ:WYNN) reported its Q4 earnings results on Wednesday, February 7, 2024 at 04:02 PM.

Here’s what investors need to know about the announcement.

Earnings

Wynn Resorts beat estimated earnings by 66.09%, reporting an EPS of $1.91 versus an estimate of $1.15.

Revenue was up $835.00 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.21 which was followed by a 5.69% drop in the share price the next day.

Here’s a look at Wynn Resorts’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 0.78 0.59 -0.01 -0.91
EPS Actual 0.99 0.91 0.29 -1.23
Revenue Estimate 1.58B 1.54B 1.37B 958.00M
Revenue Actual 1.67B 1.60B 1.42B 1.00B

To track all earnings releases for Wynn Resorts visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB